Christopher E Rudd

12PUBLICATIONS
13CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityColloid and surface chemistryPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 19, 2026
GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors.

|May 23, 2025
Immune cell infiltration into brain tumor microenvironment is mediated by Rab27-regulated vascular wall integrity.

|Jan 06, 2025
The identification of a SARs-CoV2 S2 protein derived peptide with super-antigen-like stimulatory properties on T-cells.

Thai Hien Tu, Fatima Ezzahra Bennani, Nasser Masroori

|May 03, 2024
Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity.

Thai Hien Tu, Ami Grunbaum, François Santinon

|Jun 28, 2021
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Janna Krueger, Francois Santinon, Alexandra Kazanova

|Mar 20, 2020
Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells.

Alison Taylor, Christopher E Rudd

Pageof 2

Frequent Collaborators

2 joint publications

Nicholas Rozza

2 joint publications

Chen Liu

1 joint publications

Yiwei Xiong

1 joint publications

Yulan Yi